Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease?

Inflamm Bowel Dis. 2012 Oct;18(10):1932-9. doi: 10.1002/ibd.22909. Epub 2012 Feb 16.

Abstract

Background: A disturbed epithelial barrier could play a pivotal role in ulcerative colitis (UC). We performed a family-based study analyzing in vivo gastrointestinal permeability in patients with UC, their healthy relatives, spouses, and controls.

Methods: In total, 89 patients with UC in remission, 35 first-degree relatives (UC-R), 24 nonrelated spouses (UC-NR), and 99 healthy controls (HC) were studied. Permeability was assessed by a sugar-drink test using sucrose (gastroduodenal permeability), lactulose/mannitol (intestinal permeability), and sucralose (colonic permeability). Data were correlated with clinical characteristics including medical treatment.

Results: Increased intestinal permeability was detected significantly more often in UC patients in remission (25/89, 28.1%) compared with HC (6/99, 6.1%; P < 0.001). Similar results were obtained in UC-R (7/35, 20.0%; P = 0.01 compared with HC) regardless of sharing the same household with the patients or not. No difference was found between UC-NR (3/24, 12.5%) and HC. Notably, in UC patients increased intestinal permeability was found in 12/28 patients (42.9%) with pancolitis, 7/30 (23.3%) patients with left-sided colitis, and in 2/19 (10.5%) patients with proctitis (P = 0.04). Gastroduodenal and colonic permeability were similar in all groups. Among patients on azathioprine, increased intestinal permeability was only seen in 1/18 (5.6%) patients. In contrast, in 24/70 (34.3%) patients without azathioprine, an increased intestinal permeability was found (P = 0.005).

Conclusions: An increased intestinal but not colonic permeability was found in UC patients in clinical remission that could mark a new risk factor for extensive disease location. Similar findings in healthy relatives but not spouses suggest that this barrier defect is genetically determined.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Azathioprine / therapeutic use
  • Case-Control Studies
  • Colitis, Ulcerative / drug therapy
  • Colitis, Ulcerative / genetics*
  • Colitis, Ulcerative / pathology
  • Colon / drug effects
  • Colon / metabolism
  • Colon / pathology*
  • Female
  • Genetic Predisposition to Disease*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Intestinal Absorption / genetics*
  • Intestine, Small / drug effects
  • Intestine, Small / metabolism
  • Intestine, Small / pathology*
  • Male
  • Mercaptopurine / therapeutic use
  • Permeability
  • Proctitis / drug therapy
  • Proctitis / genetics*
  • Proctitis / pathology
  • Remission Induction
  • Risk Factors
  • Spouses
  • Sucrose / pharmacokinetics*
  • Tissue Distribution

Substances

  • Immunosuppressive Agents
  • Sucrose
  • Mercaptopurine
  • Azathioprine